<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=28803"><dc:title>Machine learning-assisted diagnosis classification of primary immune dysregulation using IDDA2.1 phenotype profiling</dc:title><dc:creator>Schwitzkowski,	Malte	(Avtor)
	</dc:creator><dc:creator>Veeranki,	Sai Pavan Kumar	(Avtor)
	</dc:creator><dc:creator>Seidel,	Benedikt N.	(Avtor)
	</dc:creator><dc:creator>Kindle,	Gerhard	(Avtor)
	</dc:creator><dc:creator>Rusch,	Stephan	(Avtor)
	</dc:creator><dc:creator>Kramer,	Diether	(Avtor)
	</dc:creator><dc:creator>Seidel,	Markus G.	(Avtor)
	</dc:creator><dc:creator>Avčin,	Tadej	(Sodelavec pri raziskavi)
	</dc:creator><dc:creator>Blazina,	Štefan	(Sodelavec pri raziskavi)
	</dc:creator><dc:creator>Meško Meglič,	Karmen	(Sodelavec pri raziskavi)
	</dc:creator><dc:creator>Kopač,	Peter	(Sodelavec pri raziskavi)
	</dc:creator><dc:creator>Markelj,	Gašper	(Sodelavec pri raziskavi)
	</dc:creator><dc:subject>inborn error of immunity</dc:subject><dc:subject>IEI</dc:subject><dc:subject>primary immune regulatory disorder</dc:subject><dc:subject>PIRD</dc:subject><dc:subject>phenotype-driven disease classification</dc:subject><dc:subject>interoperable patient data</dc:subject><dc:subject>immune deficiency and dysregulation activity (IDDA) score</dc:subject><dc:subject>artificial intelligence</dc:subject><dc:subject>AI</dc:subject><dc:subject>unsupervised and supervised machine learning</dc:subject><dc:subject>ML</dc:subject><dc:subject>primary immune disorder</dc:subject><dc:subject>PID</dc:subject><dc:description>Background Immune dysregulation, including autoimmunity, autoinflammation, allergy, and malignancy predisposition, adds significant disease burden in primary immune disorders (PID) and inborn errors of immunity (IEIs). Objective We evaluated whether the 5-graded immune deficiency and dysregulation activity (IDDA2.1) score, encompassing 21 organ involvement and disease burden parameters, supports diagnosis across a wide spectrum of IEIs. Methods From April 2022 to November 2024, collaborators from 84 centers collected 1,043 IDDA score datasets from 825 patients across 89 IEIs (17 disorders with ≥10 patients each; range, 1-196 per IEI), including 177 scores from 141 treated patients. Supervised machine learning models ( k -nearest neighbors, support vector machine, logistic regression, random forest) classified patients into disease groups and ranked corresponding predictive features, while unsupervised uniform manifold approximation and projection (UMAP) visualized disease-specific clustering. Results Feature analysis reflected clinicians’ recognition of IEI patterns and confirmed internal IDDA score consistency. Phenotype profiles in treated patients remained informative, inversely reflecting anticipated treatment-dependent phenotype amelioration. UMAP effectively distinguished IEIs by IDDA2.1 profiles. Genetic disorder prediction achieved 73% overall accuracy, 70% for the correct monogenic IEI, and 93% within the top 3 predictions; classification reached 43% for IEI–International Union of Immunological Society categories and 59% for 12 “cardinal” IEIs (25 genes). Conclusions Random forest feature importance analysis can inform targeted clinical screening for key disease manifestations. The top 3 prediction approach demonstrates diagnostic potential, but improved accuracy will require larger, globally shared datasets. Small sample sizes for rare diseases highlight the necessity of broader collaboration to enhance AI-assisted clinical decision-making in the future.</dc:description><dc:date>2026</dc:date><dc:date>2026-04-08 09:53:17</dc:date><dc:type>Neznano</dc:type><dc:identifier>28803</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
